Long ramble post sorry:
The clinical trial number for the paediatric trial of Lupron (triptorelin is used in the Uk, but it’s a very similar drug that can be expected to have a similar side effect profile) is : NCT00660010
There should, in an ideal world, be more data online and filed publically. The investigators brochure would be very useful (that’s the document that they give to doctors who help to run the trial to inform them of all the animal work and preclinical work done, along with the design of the trial) however I can’t see it online. I’ve only had a quick look so it may be worth a poke around.
From the pediatric package insert:
Discontinuation of LUPRON DEPOT-PED should be considered before age 11 for females and age 12 for males. so these drugs are supposed to be taken for a short period of time only. Then you’re supposed to discontinue them and allow natural puberty to kick in. (A reminder for those reading that opposite sex hormones do not induce a correct opposite sex puberty in a child.)
And animal work .. in rats, a dose-related increase of benign pituitary hyperplasia and benign pituitary adenomas was noted at 24 months when the drug was administered subcutaneously at high daily doses (0.6 to 4 mg/kg). There was a significant but not dose-related increase of pancreatic islet-cell adenomas in females and of testicular interstitial cell adenomas in males (highest incidence in the low dose group
This bit is worth highlighting in flashing red capitals: no clinical studies have been completed in children to assess the full reversibility of fertility suppression.
www.accessdata.fda.gov/drugsatfda_docs/label/2005/020263s026lbl.pdf
So they do not know if the effects of the drug are fully reversible
The insert goes on to state that: immature male rats demonstrated tubular degeneration in the testes even after a recovery period. In spite of the failure to recover histologically, the treated males proved to be as fertile as the controls. Also, no histologic changes were observed in the female rats following the same protocol. In both sexes, the offspring of the treated animals appeared normal. The effect of the treatment of the parents on the reproductive performance of the F1 generation was not tested. The clinical significance of these findings is unknown.
What does that mean in layman’s terms? Basically that at a cellular level, the testes of the rats didn’t recover - permanent changes were seen. The rats remained fertile (remember that rats breed like, well... rats
) and the effects of the fertility of their offspring were not investigated at all.
I would be very interested to see the full data package that was submitted to the FDA. I don’t know if under whatever they have in the USA as freedom of information legislation would allow you to ask for the minutes of the pane that approved it. The actual data is confidential (and in a raw form wouldn’t be useful to you anyway)even though good practice is to be as open as possible and file redacted and processed data.
If anyone does have time to poke, the approval data for trelstar (triptorelin) would be v useful.